|Drug General Information||Top|
LCR-211; Anti-DR5 agonist chimerics mAb (cancer), Novartis; Anti-death receptor5 agonist chimeric monoclonal antibody (cancer), Novartis
|Indication||Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229]||Discontinued in Phase 1|||
|REF 1||Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026275)|
|REF 2||Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.